Health Economics›Chronic lymphocytic leukemia›Relapsed or refractory randomized data

Relapsed or refractory randomized data

Chronic lymphocytic leukemia · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Idelalisib and Ofatumumab Variant #01 Partial	—	R 4 252 351	28d	~16.3 mo	—	~18	~R 76 542 326 PFS proxy · indirect	1
O-FC Variant #01	—	R 424 251	28d	~28.9 mo	—	~32	~R 13 576 039 PFS proxy · indirect	1
Bendamustine and Rituximab (BR) and Ibrutinib Variant #02	—	R 349 542	56d	—	—	—	—	2
Venetoclax and Rituximab Variant #01	—	R 147 782	28d	—	—	—	—	2
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~44.1 mo	—	~48	~R 3 846 377 PFS proxy · indirect	15
Ibrutinib and Ublituximab Variant #01 Partial	—	R 80 133	84d	—	—	—	—	—
Acalabrutinib monotherapy Variant #01	—	R 79 217	28d	~38.4 mo	—	~42	~R 3 327 127 PFS proxy · indirect	4
Idelalisib and Rituximab Variant #02 Partial	—	R 74 707	28d	~12.6 mo	—	~14	~R 1 045 903 PFS proxy · indirect	2
FCR Variant #09	—	R 70 417	28d	~56.4 mo	—	~62	~R 4 365 849 PFS proxy · indirect	10
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	—	—	4
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	~40.7 mo	—	~45	~R 1 836 313 PFS proxy · indirect	13
Bendamustine and Rituximab (BR) and Idelalisib Variant #01 Partial	—	R 31 739	28d	~20.8 mo	—	~23	~R 729 991 PFS proxy · indirect	1
Fludarabine monotherapy Variant #01	—	R 11 691	28d	~16.5 mo	~52.9 mo	~18	~R 210 435 PFS proxy · indirect	3
Bendamustine monotherapy Variant #01	—	R 5 419	—	~18.3 mo	—	—	—	1
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~53.2 mo	—	~9	~R 468 PFS proxy · indirect	5
Ofatumumab monotherapy N/A - secondary systemic drug	—	R 2	56d	~8.1 mo	—	~5	~R 9 PFS proxy · indirect	4
Duvelisib monotherapy Variant #01 Partial	—	—	28d	~13.3 mo	—	~15	—	1

17 of 17 regimens shown